Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK, Vanderbilt Team For Obesity Drug

by Lisa M. Jarvis
February 18, 2013 | A version of this story appeared in Volume 91, Issue 7

[+]Enlarge
Credit: Joe Howell/Vanderbilt
From left: Cone, lab manager Savannah Williams, and postdoc Julien Sebag in Vanderbilt’s high-throughput screening area.
This is a photo of the Vanderbilt high-throughput screening team.
Credit: Joe Howell/Vanderbilt
From left: Cone, lab manager Savannah Williams, and postdoc Julien Sebag in Vanderbilt’s high-throughput screening area.

GlaxoSmithKline and Vanderbilt University will work together to develop drugs to treat severe obesity. Led by biologist Roger Cone, Vanderbilt scientists have discovered positive allosteric modulators of melanocortin-4 receptor (MC4-R), a protein involved in body weight regulation. In exchange for access to the MC4-R modulators, GSK will provide Vanderbilt with three years of research support as well as milestone payments on any drug candidates developed. The partners hope to have an MC4-R modulator in Phase I studies by 2016.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.